Daptomycin

證據等級: L5

預測適應症: 10 個

Daptomycin: From Gram-Positive Bacterial Infections to Osteoarthritis

⚠️ Research Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.

One-Sentence Summary

Daptomycin is a cyclic lipopeptide antibiotic currently approved for serious Gram-positive bacterial infections, including complicated skin and skin structure infections, Staphylococcus aureus bacteremia, and right-sided infective endocarditis. The TxGNN model assigns its highest prediction score to Osteoarthritis (score 99.86%), yet a closer review reveals that all 10 supporting publications relate to managing bacterial infections in joint-replacement patients—not to treating osteoarthritis itself—suggesting a knowledge-graph context conflation rather than a genuine repurposing signal. A second-ranked prediction, Rheumatoid Arthritis (score 99.84%), carries more credible early-stage mechanistic evidence and is highlighted separately in this report.

Quick Overview

Item	Content
Original Indication	Gram-positive bacterial infections (skin/skin structure infections, S. aureus bacteremia, right-sided endocarditis)
Predicted New Indication	Osteoarthritis (Rank #1 by TxGNN)
TxGNN Prediction Score	99.86%
Evidence Level	L4 — observational / indirect clinical data only
India Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Daptomycin is a naturally-derived cyclic lipopeptide antibiotic produced by Streptomyces roseosporus. Although detailed MOA data is not available in the current evidence pack, its mechanism is well-characterised in the literature: daptomycin binds to bacterial cell membranes in a calcium-dependent manner, causing rapid membrane depolarisation, loss of intracellular potassium, and eventual cell death. This bactericidal activity is highly selective for Gram-positive organisms and does not extend to mammalian cell membranes at therapeutic concentrations.

Osteoarthritis (OA) is a chronic, degenerative joint disease driven by cartilage degradation, subchondral bone remodelling, and low-grade synovial inflammation—mechanisms that are entirely distinct from bacterial cell-membrane disruption. There is no established pharmacological bridge between daptomycin’s antibiotic mechanism and any known OA disease-modifying pathway (e.g., chondroprotection, metalloproteinase inhibition, or RANKL modulation).

The TxGNN high score most likely reflects a knowledge-graph context conflation: the graph encodes that daptomycin is used to treat bone and joint infections (prosthetic joint infections, PJIs) in patients who often have underlying OA, creating a semantic proximity between “daptomycin → bone/joint disease” that the model interprets as a repurposing signal. All 10 retrieved publications confirm this pattern—they document daptomycin for treating infections complicating joint-replacement surgery, not for treating OA itself.

Clinical Trial Evidence

No clinical trials for Daptomycin in osteoarthritis are currently registered.

Literature Evidence

All retrieved publications relate to treating prosthetic joint infections (PJIs) in orthopaedic patients—not to treating osteoarthritis as a disease entity. This finding reinforces the context-conflation interpretation.

PMID	Year	Type	Journal	Key Findings
17999973	2008	Retrospective Comparative	J Antimicrob Chemother	Daptomycin vs. standard therapy for osteoarticular infections (OAIs) associated with S. aureus bacteremia
22511636	2012	Case Series	J Antimicrob Chemother	Daptomycin efficacy and safety for hip and knee periprosthetic joint infections (PJIs)
22854340	2012	In Vitro Susceptibility Study	J Antibiotics	Daptomycin susceptibility of S. aureus and S. epidermidis from prosthetic joint infections
23312602	2013	Expert Network Survey	Int J Antimicrob Agents	Current management practices for PJIs; daptomycin as a preferred agent for MRSA/MSSA PJI
23519823	2013	Retrospective Multicenter	Int Orthopaedics	High-dose daptomycin + rifampicin for Gram-positive osteoarticular infections; safety and efficacy
21477701	2010	Registry Study (EU-CORE)	Med Clin	Real-world daptomycin use across European countries including orthopaedic infections
25650692	2015	Microbiological Profile Study	Surg Infect	10-year antibiotic susceptibility trends for staphylococci causing osteoarticular infections
26235888	2015	Retrospective Multicenter	Int J Antimicrob Agents	High-dose daptomycin (>6 mg/kg) for complicated bone/joint and implant-associated infections
32206362	2020	Case Report	Case Rep Orthop	Septic arthritis masquerading as osteoarthritis; daptomycin used in management
41853106	2026	Case Report	ASM Case Reports	Septic arthritis due to Corynebacterium propinquum in a patient with pre-existing joint disease

India Market Information

Daptomycin is currently not marketed in India and has no registered product licences on file. No authorisation table can be generated.

Notable Secondary Prediction: Rheumatoid Arthritis (Rank #2)

Although the primary focus of this report is the top TxGNN prediction (osteoarthritis), the rheumatoid arthritis prediction (TxGNN score 99.84%, rank #2) warrants specific attention as it carries a more credible, though still early-stage, mechanistic rationale.

Two 2025 publications provide direct mechanistic evidence:

PMID	Year	Type	Journal	Key Findings
39571268	2025	Animal Study (CIA model)	Int Immunopharmacol	Daptomycin alleviates collagen-induced arthritis in mice by suppressing TNF-α, IL-1β, IL-6 and inhibiting the NF-κB signalling pathway—first demonstration of anti-RA activity
40923559	2025	In Vitro + Animal Study	J Med Chem	Novel daptomycin-derived cyclic lipopeptides with superior anti-RA activity; structural optimisation confirms the anti-inflammatory pharmacophore of the daptomycin scaffold

Assessment: The NF-κB pathway is a central driver of RA pathogenesis, and these findings provide biological plausibility. However, all evidence remains at the animal-model level (Evidence Level L4). No human trials have been initiated. This constitutes a legitimate Research Question rather than an actionable repurposing candidate.

Safety Considerations

Drug–Drug Interactions

12 interactions identified (DDInter database). The most clinically significant are listed below:

Interacting Drug	Severity	Clinical Relevance
Rosuvastatin	Moderate	Concurrent statin use increases risk of daptomycin-associated myopathy and rhabdomyolysis
Simvastatin	Moderate	Same mechanism as above; statin dose reduction or temporary discontinuation recommended
Cyclosporine	Moderate	Potential for increased daptomycin plasma levels and additive nephrotoxicity
Mycophenolic acid	Moderate	Pharmacokinetic interaction; monitoring advised in immunosuppressed patients
Ibuprofen	Moderate	NSAIDs may reduce renal clearance of daptomycin; risk of nephrotoxicity
Diclofenac	Moderate	Same mechanism as above
Celecoxib	Moderate	Same mechanism as above
Ethinylestradiol	Moderate	Potential alteration in hormonal contraceptive efficacy during antibiotic therapy
Picosulfuric acid	Moderate	Bowel-preparation context; monitor electrolytes
Iobenguane (I-131)	Moderate	Potential interference with radioiodine uptake in diagnostic/therapeutic settings
Warfarin	Minor	Minor effect on anticoagulation; INR monitoring advisable
Dicoumarol	Minor	Similar to warfarin; minor interaction

Critical Note (Gout Safety Signal): A published case report (PMID 36693494, 2023) documents daptomycin-induced rhabdomyolysis leading to acute gouty arthritis via hyperuricaemia. This is an adverse drug reaction, not a repurposing opportunity. The TxGNN rank-4 “gout” prediction (score 99.79%) should be interpreted as a safety hazard signal, not as therapeutic potential.

Please refer to the package insert for full warnings and contraindications, which were not available in the current evidence pack.

Comprehensive Prediction Landscape

Rank	Predicted Indication	TxGNN Score	Evidence Level	Assessment
1	Osteoarthritis	99.86%	L4	⛔ Context conflation — all evidence is PJI management, not OA treatment
2	Rheumatoid Arthritis	99.84%	L4	🔬 Research Question — animal model mechanistic evidence (NF-κB pathway)
3	Osteoarthritis Susceptibility	99.79%	L5	⛔ Semantic drift — literature addresses infection susceptibility, not OA genetics
4	Gout	99.79%	L5	⚠️ Adverse effect signal — daptomycin causes gout via rhabdomyolysis
5–10	Rare skeletal dysplasias (pseudoachondroplasia, brachyolmia, brachydactyly-syndactyly, etc.)	99.47–99.74%	L5	⛔ KG skeletal disease cluster effect — zero literature, no mechanistic basis

Conclusion and Next Steps

Decision: Hold

Rationale: The top TxGNN prediction (osteoarthritis, score 99.86%) is a false-positive driven by knowledge-graph semantic proximity between daptomycin’s antibiotic use in orthopaedic infections and the underlying OA diagnosis in those patients. There is no mechanistic pathway connecting daptomycin to OA treatment, and none of the 10 retrieved publications support osteoarthritis as a therapeutic indication. The gout prediction (rank 4) represents an active safety warning rather than a repurposing opportunity.

The one signal worth monitoring is: The rheumatoid arthritis prediction, which has preliminary but biologically coherent evidence from two 2025 animal studies demonstrating NF-κB-mediated anti-inflammatory effects.

To proceed further with the RA research question, the following steps are needed:

Confirm daptomycin MOA data from DrugBank to characterise the anti-inflammatory pharmacophore
Retrieve CDSCO (India) and global package insert data for complete warning and contraindication profiles
Commission or identify in vitro human synoviocyte/macrophage studies to validate NF-κB pathway inhibition in human cell lines
Assess whether IV-only administration route is compatible with a chronic RA treatment paradigm (oral bioavailability is negligible)
Design a Phase 0/1 translational study protocol if preclinical human-cell evidence is confirmed
Conduct a formal statin co-medication risk assessment given the myopathy interaction profile, relevant for RA patients on concomitant lipid-lowering therapy

Report generated: 2026-04-04 | Evidence Pack: TW-DB00080-multi v4 | Data cutoff: 2026-04-04 For research use only. All repurposing candidates require clinical validation before any therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.